TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial. The study measured the effect of hydromethylthionine mesylate (HMTM) on neurofilament light change (NfL) – a vital brain neurodegeneration biomarker.
https://www.pharmatimes.com/news/taurxs_deliver_alzheimers_disease_therapy_results_1494575